Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease  by Fowkes, F. Gerald R. et al.
Reduced lung function in patients with abdominal
aortic aneurysm is associated with activation
of inflammation and hemostasis, not smoking
or cardiovascular disease
F. Gerald R. Fowkes, PhD,a Chantelle L. C. Anandan, PhD,a Amanda J. Lee, PhD,b
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Objective: Abdominal aortic aneurysms often coexist with reduced lung function and chronic obstructive pulmonary
disease (COPD). These conditions are each associated with cigarette smoking, cardiovascular disease, and evidence of
increased inflammatory and hemostatic activity. The aim of this study was to determine if these factors accounted for the
link between aneurysms and pulmonary disease.
Methods: The design was a case-control study comparing patients with an asymptomatic abdominal aortic aneurysm with
population-based controls without an aneurysm. Aneurysms were diagnosed by ultrasound scan, and pulmonary function
was measured by respiratory questionnaire and spirometry. Activation of inflammation and hemostasis was measured by
assay of plasma interleukin-6 (IL-6), fibrinogen, von Willebrand factor (vWF), tissue plasminogen activator (tPA)
antigen, fibrin D-dimer, and plasmin antiplasmin complexes.
Results: Cases with an abdominal aortic aneurysm (n  89) had more COPD and worse expiratory lung function as
measured by forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) than controls (n 98) (FEV1,
1.9 vs 2.2 L, P < .01; FEV1/FVC, 0.67 vs 0.75, P < .001) and did not differ in restrictive function (FVC, 2.9 vs 3.0 L,
P .33). Cases also had higher levels of lifetime cigarette smoking (30 vs 24 pack-years, P< 0.01), cardiovascular disease
(35% vs 18%, P  .01), plasma fibrinogen (3.5 vs 3.1 g/L, P  .02), IL-6 (2.8 vs 1.8, pg/mL, P < .001), plasmin
antiplasmin complexes (596 vs 384 g/L, P  .01), and D-dimer (442 vs 93 ng/mL, P < .001). On multiple logistic
regression analysis of lung function and COPD on the risk of aneurysm, both cigarette smoking and cardiovascular
disease had little effect on the relationships. For the markers of activated inflammation and hemostasis, plasmin
antiplasmin complexes andD-dimer had themost important confounding effect on the odds ratios. All markers combined
had a substantial effect: odds ratio of aneurysm for a one standard deviation decrease in FEV1 fell from 2.3 (95%
confidence interval [CI], 1.5 to 3.5) (P < .01) to 1.3 (95% CI, 0.55 to 2.4) (P > .05).
Conclusion: The association between reduced respiratory function and abdominal aortic aneurysm was not accounted for
by cigarette smoking or cardiovascular disease. We hypothesize that activation of inflammation and hemostasis in
response to injury may be an important explanation of the association between aneurysm formation and reduced
respiratory function. Further studies are required to test this hypothesis. ( J Vasc Surg 2006;43:474-80.)Reduced lung function occurs more commonly in pa-
tients with abdominal aortic aneurysms (AAAs)1-5 and is
related to an increased risk of rupture.6-8 Atherosclerotic
cardiovascular diseases such as coronary heart disease, pe-
ripheral arterial disease, and stroke are also associated with
impaired lung function9-12 and with the occurrence of
AAAs.13 Thus, cardiovascular disease could be a major
confounding factor for the association between lung func-
From the Wolfson Unit for Prevention of Peripheral Vascular Diseases,
University of Edinburgha; Department of General Practice & Primary
Care, University of Aberdeen, Foresterhill Health Centreb; Cardiovascu-
lar andMedical Sciences Division, University of Glasgowc; and University
Hospitals, Coventry and Warwickshire NHS Trust.d
Competition of interest: none.
Funding was provided by the British Heart Foundation.
Correspondence: Professor Gerald Fowkes, Wolfson Unit for Prevention of
Peripheral Vascular Diseases, University of Edinburgh, Teviot Place, Edin-
burgh EH8 9AG, United Kingdom (e-mail: Gerry.Fowkes@ed.ac.uk).
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2005.11.018
474tion and aneurysm. Likewise, cigarette smoking is an im-
portant risk factor for respiratory disease, cardiovascular
disease, and AAA13 and could have a role in explaining the
association between lung function and aneurysm.
Inflammation is an important component of aneurys-
mal disease as well as chronic respiratory disease and ath-
erosclerosis. In patients with an AAA, proinflammatory
cytokines have shown increased expression in aneurysmal
aortic tissue14 and higher circulating levels than in controls
without an AAA.15 Increased cytokine activity may induce
degradation of components of the extracellular matrix in
the arterial wall leading to aneurysm formation16 and,
furthermore, may enhance coagulation by, for example,
upregulation of plasma fibrinogen. The association be-
tween reduced lung function and aortic aneurysm could
conceivably be mediated or due to a concomitant effect of
systemic inflammation and hemostasis.
The aim of this study was to determine whether an
association between impaired lung function and AAA was
independent or was influenced by the effects of smoking,
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tion and hemostasis.
METHODS
The study design was a case-control study comparing
cases of asymptomatic AAA with controls without an aneu-
rysm. This investigation was nested partly within the Edin-
burgh Artery Study, a population cohort study that began
in 1988. At baseline, 1592 men and women aged 55 to 74
years were selected randomly from the general population
from the age-sex registers of 11 general practices in the City
of Edinburgh. Subjects attended a clinic for a comprehen-
sive examination that included measurement of cardiovas-
cular risk factors and disease. Follow-up examinations were
conducted at 5 and 12 years and included ultrasound
screening for AAAs. Continuous assessment to monitor
cardiovascular events took place during the follow-up pe-
riod. Further details of the design of the Edinburgh Artery
Study have been published.17-19 The study was approved
by the Lothian Health Board Ethics Committee.
The recruitment target was 100 cases and 100 controls,
especially to ensure a reasonably representative sample of
asymptomatic aneurysms. The intention was to select most
cases from the Edinburgh Artery Study, but owing to the
low numbers identified, most cases were selected consecu-
tively from the elective surgical waiting list at the Royal
Infirmary of Edinburgh.Cases were included if they had an
anteroposterior aortic diameter of at least 3 cm confirmed
at the study clinic. The aortic diameter was measured by
ultrasound scan using a 3 MHz transducer and an ATL
UM9 HDI (Bothell, Wash) system, and the maximum of
three readings was taken as the diameter. The few cases
derived from the Edinburgh Artery Study were identified at
the 12-year examination. An Aloka 500 portable scanner
(Tokyo, Japan) was used in the homes of a few subjects who
were unable to attend the clinic.
Controls were all selected from within the Edinburgh
Artery Study population. Potential controls were stratified
into 5-year age and sex groups, and matched controls were
randomly selected from these strata by using random num-
ber tables. They were oversampled to allow for nonatten-
dance at the clinic. Ultrasound screening at the 12-year
examination confirmed the absence of aortic aneurysm.
Cases and controls also completed a questionnaire on
smoking the World Health Organization (WHO) ques-
tionnaire inquiring about angina, intermittent claudica-
tion, and previous myocardial infarction20; and the Medical
Research Council questionnaire was used for respiratory
symptoms.21 Height was measured without shoes to the
nearest 5 mm by using a stadiometer, weight was measured
without outer clothing to the nearest 100 g using a digital
scale (Soehnle, Murrhardt, Germany). Respiratory func-
tion, determined by forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), and peak expiratory
flow rate (PEFR), was measured three times by using a
hand-held spirometer (Vitalograph Ltd, Buckingham,
United Kingdom). Systolic and diastolic blood pressure
was measured in the right arm by using a Hawksley randomzero sphygmomanometer (Sussex, United Kingdom) and
systolic pressures in the right and left ankles with the aid of
a Doppler ultrasound probe (Sonicaid, Sussex, United
Kingdom). A 12-lead electrocardiogram (ECG) was re-
corded. A 20-mL venous blood sample was taken without
tourniquet, centrifuged, and aliquots of citrated plasma
were stored at 40oC. These measures were included in
the Edinburgh Artery Study 12-year examination with the
exception of the respiratory symptoms and lung function
tests, which were assessed only for this case-control study.
In the laboratory, the following markers of activated
inflammation and hemostasis were measured: plasma
interleukin-6 (IL-6) by high sensitivity enzyme-linked im-
munoabsorbent assay (ELISA) (R & D Systems, Minneap-
olis, Minn), fibrinogen (Clauss assay), von Willebrand fac-
tor (vWF) (ELISA, DAKO, Glostrup, Denmark), tissue
plasminogen activator (tPA) antigen, fibrin D-dimer, and
plasmin-antiplasmin complexes (ELISAs, Biopool, Ven-
tura, Calif). The selection of factors was dependent on
assays conducted at the 12-year follow-up examination in
the Edinburgh Artery Study. C-reactive protein (CRP) was
assayed only at baseline 12 years earlier and was therefore
not included in the current analysis; assays were not avail-
able for serum proteases including matrix metalloprotein-
ases.
Measures of respiratory function consisted of PEFR,
FEV1, FVC, and the FEV1/FVC ratio as well as the per-
centage of subjects with values derived from a healthy
reference population of known age, sex, height, and ethnic
group.22 The maximum value of the three repeat respira-
tory tests was used in the analyses. A history of respiratory
symptoms suggestive of chronic bronchitis was considered
to be present if a positive response was given to questions
on the usual occurrence of cough or phlegm first thing in
the morning in winter or of wheeze (attacks of wheezing or
whistling in the chest).21
A modification of the Global Initiatives for Chronic
Obstructive Lung Disease (GOLD) definitional criteria23
was used to classify subjects into the mutually exclusive cate-
gories of severe COPD (FEV1/FVC0.7 and FEV150%
predicted), moderate COPD (FEV1/FVC0.7 and FEV1
50% to 80% predicted), mild COPD (FEV1/FVC 0.7
and FEV1 80% predicted), symptoms only (presence of
symptoms in absence of lung function abnormality), re-
strictive lung disease (FEV1 0.7 and FVC 80% pre-
dicted), or no lung disease (none of the above).
Cigarette-smoking status was defined by the three cat-
egories of current, ex, and never. Lifetime cigarette con-
sumption was analyzed by pack-years (number of years
smoked  average number of packs smoked per day). The
distribution was skewed with a few heavy smokers, and so a
square root transformation was used. Body mass index
(BMI) was calculated as kg/m2. The ankle brachial index
(ABI) was calculated for each leg by dividing ankle pressure
by arm systolic pressure and the lower of the left and right
indices was used in the analysis. The presence of cardiovas-
cular disease was defined as any one of the following:
myocardial infarction (any two of positive WHO question-
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myocardial infarction, or ECG evidence), angina (positive
WHO questionnaire plus either ECG evidence of ischemia
or subject remembering that a doctor had diagnosed an-
gina), or intermittent claudication (positive WHO ques-
tionnaire). Diabetes mellitus was not specified in the anal-
ysis because of very small numbers in the study sample.
The analysis was carried out according to a predeter-
mined statistical plan by using SPSS version 12 (SPSS,
Chicago, Ill) for Windows (Microsoft, Redmond, Wash)
and consisted of a comparison of clinical and blood assay
data between cases and controls. Logistic regression was
used to assess univariate differences in risk factors between
cases and controls. The distributions of plasma fibrinogen,
tPA and vWF were skewed, and so square root transforma-
tions were used. A natural log transformation was used for
D-dimer, IL-6, and plasmin anti-plasmin complexes. Lo-
gistic regression was used to calculate age, sex, and height-
adjusted odds ratios for aneurysm according to lung func-
tion and severity of COPD. Those with restrictive lung
disease were excluded from this analysis because it is a type
of disease different from COPD. Odds ratios were further
adjusted for inflammatory and hemostatic factors, smoking,
and cardiovascular disease. Throughout all analyses, a two-
sided P  .05 was used to denote statistical significance. A
variable was considered to have a possible confounding
effect if the odds ratio changed by 20%.
RESULTS
The study sample comprised 89 cases of asymptomatic
AAA, of which 81 were selected from the waiting list for
elective aneurysm repair in the Royal Infirmary of Edin-
burgh and eight were identified by ultrasound scanning in
the Edinburgh Artery Study. Of the 139 controls selected,
98 attended for examination. No controls were subse-
quently found to have an aneurysm. The median aneurysm
diameter (interquartile range) of cases was 4.5 cm (3.9 to
5.1 cm) and controls, 2.0 cm (1.8 to 2.3 cm).
The demographic, risk factor, and cardiovascular status
of the cases and controls is shown in Table I. The mean age
of all subjects was 73.5 years, and 72% were men. As
expected from the matching scheme, no significant differ-
ences in age or sex were found between cases and controls.
BMI was lower in cases than controls (P  .03), whereas
systolic blood pressure and a history of cigarette smoking
were significantly higher in cases (P  .01). Indicators of
cardiovascular disease were also more common in cases
(P  .01). About one third of cases had evidence of
previous myocardial infarction, angina, or claudication.
The mean ABI was significantly lower in cases than in
controls (P  .001).
Plasma levels of fibrinogen, IL-6, plasmin antiplasmin
complexes, and D-dimer were significantly higher in aneu-
rysm cases than controls (Table II). The differences in
median levels of IL-6 (P  .001), plasmin antiplasmin
complexes (P  .01), and D-dimer (P  .001) were sub-
stantial. Table III shows that lung function was worse in
aneurysm cases than in controls. FVC was slightly butnonsignificantly reduced, whereas the measures of expira-
tory flow (FEV1 and PEFR)were significantly reduced (P
.01), resulting in a lower FEV1/FVC ratio in cases than in
controls (0.67 vs 0.75, P  .001). Similar differences were
found for the predicted results according to age, sex, and
height. The frequency of COPD was also found to differ
between cases and controls (P  .001), with more cases
having severe, moderate, or mild COPD relative to no lung
disease compared with controls.
The extent to which the difference in lung function tests
between cases and controls was independent of markers of
activated inflammation and hemostasis, cigarette smoking,
and the presence of cardiovascular disease is demonstrated
in the logistic regression models shown in Table IV. The
odds ratios for aneurysm (95% confidence intervals [CI])
for a one standard deviation decrease in FEV1, PEFR, and
FEV1/ FVC, adjusting for age, sex, and height, were each
2 (P  .01). Adjusting for cardiovascular disease or
cigarette smoking had no important effect on the odds
ratios. Adjusting for each of the inflammatory and hemo-
static markers, only plasmin antiplasmin complexes and
D-dimer had a confounding effect, reducing odds ratios by
20%. The most notable effect was for D-dimer. Adjusting
for all the inflammatory and hemostatic markers also had a
substantial effect, reducing the odds ratios to nonsignifi-
cant levels. Further adjustment for smoking, cardiovascular
Table I. Subject characteristics and cardiovascular disease
in cases of abdominal aortic aneurysm and controls
Cases (n  89) Controls (n  98) P*
Age (years) 73.5  0.5 73.5  0.5 .95
Sex (% male) 64 (71.9) 70 (71.4) .94
Height (cm) 166.9  1.0 166.6  0.9 .81
Weight (kg) 70.0  1.4 73.0  1.4 .12
Body mass index
(kg/m2) 25.0  0.4 26.3  0.4 .03
Blood pressure
(mm Hg)
Systolic 153.9  2.4 145.7  2.1 .01
Diastolic 80.1  1.6 78.2  1.2 .32
Cigarette Smoking
Current smoker 28 (31.5) 12 (12.2) .01
Ex-smoker 51 (57.3) 55 (56.1) .01
Never smoker 8 (9.0) 31 (31.7) .01
Pack-years† 30.1  0.1 23.8  0.1 .01
Cardiovascular
disease
Myocardial
infarction 10 (11.2) 10 (6.1) .22
Angina 11 (12.4) 6 (10.2) .64
Intermittent
claudication 19 (21.3) 8 (8.2) .01
All cardiovascular‡ 31 (34.8) 18 (18.4) .01
Ankle brachial index 0.81  0.03 1.01  0.02 .001
Data are mean  SE or number (%). Totals may not correspond to all cases
and controls due to missing data and/or duplication.
*Calculated using logistic regression.
†Means derived from square root distributions and back transformed. Only
current and ex-smokers included.
‡Myocardial infarction and/or angina and/or intermittent claudication.disease, and ABI had little effect.
miss
tory a
ontro
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inflammation and hemostasis, smoking, and cardiovascular
disease on the relationships between increasing severity of
COPD on the risks of aneurysm. Lifetime smoking and
cardiovascular disease had little influence on the magnitude
of the odds ratio. Plasmin antiplasmin complexes and D-
dimer were the only markers that had a specified confound-
ing effect in reducing the odds of aneurysm for increasing
severity of COPD. The combined effect of all the inflam-
matory and hemostatic markers was comparable. Further
adjustment for smoking, cardiovascular disease, and ABI
had little effect.
Finally, in logistic regressions on aortic aneurysm,
which included one measure of lung function in each
model and all inflammatory and hemostatic factors, smok-
Table II. Median (interquartile range) of plasma inflamm
aneurysm and controls
Cases (n  89)
Fibrinogen (g/L) 3.5 (2.9-4.1)
Interleukin-6 (pg/mL) 2.8 (2.0-4.2)
Plasmin antiplasmin (g/L) 596.0 (432.0-877
vWF (IU/dL) 122.5 (98.0-150.
tPA antigen (ng/mL) 7.9 (6.0-11.1)
D-dimer (ng/mL) 441.5 (198.8-771
vWF, von Willebrand factor; tPA, tissue plasminogen activator.
Medians are not all based on total numbers of cases and controls due to few
*Calculated for logistic regression models for aneurysm with each inflamma
Table III. Measures of lung function and chronic obstruc
and controls
Cases n  89 Contro
FVC (L) 2.9  0.1 3.0
FVC (% predicted) 81.5  2.0 86.6
FEV1 (L) 1.9  0.1 2.2
FEV1 (% predicted) 74.4  2.5 88.9
FEV1/FVC 0.67  0.02 0.75
FEV1/FVC (% predicted) 90.8  2.1 102.2
PEFR (L/min) 278.0  14.0 340.1
PEFR (% predicted) 41.6  2.1 51.6
COPD† (%) (n  87) (n 
Severe COPD 13 (14.9) 4 (
Moderate COPD 20 (23.0) 11 (
Mild COPD 15 (17.2) 7 (
Restrictive lung disease 19 (21.8) 23 (
Symptoms only 14 (16.1) 25 (
No lung disease 6 (6.9) 24 (
OR, Odds ratio; CI, confidence interval; FVC, forced vital capacity; FEV1,
chronic obstructive pulmonary disease.
Figures are mean  SE or number (%) except for % predicted, which is % o
Odds ratios for the lung function measures are unadjusted and are per 1SD d
comparing each category to no lung disease.
*Calculated by using logistic regression.
†Severe COPD (FEV1/FVC 0.70 and FEV1 50% predicted), modera
(FEV1/FVC 0.70 and FEV1 80% predicted), restrictive lung disease (F
symptoms in the absence of any lung function abnormality) and no lung di
‡Represents significance of odds ratio in each COPD group compared with
§Represents significance of difference in COPD overall between cases and cing, cardiovascular disease, and ABI, D-dimer was found tobe strongly and independently related to aneurysm in each
model. The odds ratio (95% CI) for one SD increase in
D-dimer in each model was 5.9 (2.7, 12.6) with FEV1, 5.1
(2.5, 10.6) with PEFR; 4.6 (2.3, 9.5) with FEV1/FVC,
and 5.0 (2.4, 10.3) with COPD (all P  .001).
DISCUSSION
The principal findings of this study were that individu-
als with an AAA had worse lung function and more COPD
than controls without AAAs. The lung function affected
was primarily obstructive (reduced expiration) and not restric-
tive (reduced vital capacity). Aneurysm cases had higher
levels of cigarette smoking, cardiovascular disease, and
plasma levels of markers of inflammation and hemostasis.
The associations between lung function, COPD, and aneu-
and hemostatic factors in cases of abdominal aortic
Controls (n  98) P*
3.1 (2.7-3.6) .02
1.8 (1.3-2.7) .001
383.5 (273.8-485.5) .01
123.0 (101.0-152.0) .55
8.6 (6.8-11.5) .64
93.0 (57.8-158.8) .001
ing assays.
nd hemostatic factor entered as continuous variable.
pulmonary disease in cases of abdominal aortic aneurysm
98 OR (95% CI) of aneurysm P*
1 1.15 (0.86, 1.55) .33
8 1.32 (0.98, 1.79) .07
1 1.60 (1.17, 2.19) .01
2 1.98 (1.41, 2.78) .001
01 1.99 (1.41, 2.81) .001
5 2.09 (1.46, 2.99) .001
.5 1.60 (1.17, 2.19) .01
9 1.81 (1.28, 2.56) .001
13.00 (3.10, 54.54) .001‡
) 7.27 (2.28, 23.16) .001‡
8.57 (2.41, 30.43) .001‡ .001§
) 3.30 (1.12, 9.74) .03‡
) 2.24 (0.74, 6.78) .15‡
)
expiratory volume in 1 second; PEFR, peak expiratory flow rate; COPD,
t in healthy persons of same age, sex and height  SD.
se standardized. COPD is fitted as categoric variable and the odds ratios are
PD (FEV1/FVC 0.70 and FEV1 50 to 80% predicted), mild COPD
0.70 and FVC 80% predicted) symptoms only (presence of respiratory
ng disease.
ls.atory
.8)
2)
.0)tive
ls n 
 0.
 1.
 0.
 2.
 0.
 1.
 14
 1.
94)
4.3)
11.7
7.4)
24.5
26.6
25.5
forced
f resul
ecrea
te CO
EV1
sease.
no lurysms were only marginally affected by smoking and cardio-
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nonsignificant on adjusting for themarkers of inflammation
Table IV. Logistic regressions of FEV1, PEFR and FEV1/
cardiovascular disease, and inflammatory and hemostatic fa
Adjusted for age, sex, and height plus:
FEV1
1 SD decrease (0
— 2.3 (1.5, 3.5
Smoking (pack-years) 2.1 (1.4, 3.3
Cardiovascular disease‡ 2.2 (1.4, 3.3
Fibrinogen (g/L) 2.0 (1.3, 3.2
Interleukin-6 (pg/mL) 1.9 (1.2, 3.1
Plasmin antiplasmin (g/L) 1.5 (1.0, 2.5
vWF (IU/dL) 2.5 (1.6, 3.9
tPA antigen (ng/mL) 2.3 (1.5, 3.6
D-dimer (ng/mL) 1.2 (0.7, 2.0
All inflammatory and hemostatic factors§ 1.3 (0.7, 2.4
All inflammatory and hemostatic factors§,
smoking, cardiovascular disease, ABI 1.0 (0.5, 2.0
FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity; PEF
activator; ABI, ankle brachial index.
*P  .01.
†P  .05 (P values derived from the logistic regressions).
‡Cardiovascular disease: myocardial infarction and/or angina and/or interm
§Fibrinogen, interleukin-6, plasmin antiplasmin, vWF, tPA, D-dimer.
Table V. Logistic regressions of chronic obstructive
pulmonary disease on abdominal aortic aneurysm
adjusting for smoking, cardiovascular disease and
inflammatory and hemostatic factors
Adjusted for age, sex, and height, plus:
Odds ratio (95% CI) of
aneurysm for an
increase in one category
of COPD severity*
— 1.7 (1.3, 2.1)†
Smoking (pack-years) 1.6 (1.3, 2.1)†
Cardiovascular disease 1.6 (1.3, 2.0)†
Fibrinogen (g/L) 1.5 (1.2, 1.9)†
Interleukin-6 (pg/mL) 1.5 (1.2, 1.9)‡
Plasmin antiplasmin (g/L) 1.3 (1.1, 1.7)‡
vWF (IU/dL) 1.7 (1.3, 2.1)†
tPA antigen (ng/mL) 1.6 (1.3, 2.0)†
D-dimer (ng/mL) 1.3 (1.0, 1.7)
All inflammatory and hemostatic factors§ 1.4 (1.0, 1.9)
All inflammatory and hemostatic
factors,§ smoking, cardiovascular
disease, ABI 1.3 (0.9, 1.9)
COPD, Chronic obstructive pulmonary disease; vWF, von Willebrand fac-
tor; tPA, tissue plasminogen activator; ABI, ankle brachial index.
*Categories of severity of COPD: severe (FEV1/FVC 0.7 and FEV1 
50% predicted), moderate (FEV1/FVC 0.7 and FEV1 80% predicted),
mild (FEV1/FVC 0.7 and FEV1 50 to 80% predicted), symptoms only
(presence of symptoms in absence of lung function abnormality), no disease
(none of the above and no restrictive lung disease (FEV1 0.7 and FVC
80% predicted). These categories were fitted as ordinal variables.
†P  .01.
‡P  .05 (P derived from logistic regressions).
§Fibrinogen, interleukin-6, plasmin antiplasmin, vWF, tPA, D-dimer.and hemostasis.Our results confirm the findings of other clinical1,2 and
community studies3-5 showing an association between
COPD and AAAs. In veterans screened in the United
States,3 men born in 1914 in Malmo,4 and in a population
cross-sectional study in Denmark,5 evidence of COPD was
related to an increased risk of aneurysm. Impaired lung
function was found in a case-control study in Japan1 to be
more common in cases of thoracic and abdominal aneu-
rysms than in coronary heart disease patients and healthy
controls.
The degree of respiratory impairment may be impor-
tant; in a consecutive group of emphysema patients, those
with the lowest FEV1/FVC had a higher prevalence of
aneurysms than those with a moderate reduction.2 Chronic
pulmonary disease has also been related to the risk of
aneurysm rupture in autopsy series6 and in the follow-up of
aneurysm patients,7,8 although, surprisingly, reduced aneu-
rysm growth was found in one study.5 However, the overall
evidence indicates that an association does exist between
impaired lung function and the presence of AAAs.
AAAs occur frequently in the presence of atherosclero-
sis13 and its clinical manifestations.9-12 Reduced expiratory
flow has been associated longitudinally with a higher inci-
dence of fatal and nonfatal coronary heart disease and
stroke.9-11 Furthermore, impaired lung function has been
associated with subclinical cerebral infarction and white
matter lesions24 as well as carotid stenosis and a low ABI.12
We have shown, however, that the association between
both reduced expiratory flow (FEV1 and PEFR) and
COPDwith the risk of aortic aneurysm was independent of
concomitant cardiovascular disease. The Aneurysm Detec-
tion And Management (ADAM) study3 in the United
States also found the association to be independent of
on abdominal aortic aneurysm adjusting for smoking,
ds ratio of aneurysm (95% confidence interval)
PEFR FEV1/FVC ratio
1 SD decrease (139.78L/min) 1 SD decrease (0.12)
2.0 (1.4, 3.0)* 2.2 (1.5, 3.1)*
1.9 (1.3, 2.8)* 2.0 (1.4, 3.0)*
1.9 (1.3, 2.9)* 2.1 (1.5, 3.1)*
1.9 (1.2, 2.8)† 2.1 (1.4, 3.1)*
1.8 (1.2, 2.7)* 1.9 (1.3, 2.8)*
1.5 (1.0, 2.2) 1.8 (1.2, 2.8)*
2.1 (1.4, 3.3)* 2.6 (1.7, 4.0)*
2.0 (1.3, 3.0)* 2.3 (1.5, 3.4)*
1.2 (0.7, 1.8) 1.5 (0.9, 2.4)
1.2 (0.7, 2.0) 1.6 (0.9, 2.9)
1.1 (0.7, 1.9) 1.5 (0.8, 2.7)
k expiratory flow rate; vWF, vonWillebrand factor; tPA, tissue plasminogen
t claudication.FVC
ctors
Od
.70L)
)*
)*
)*
)*
)*
)
)*
)*
)
)
)
R, pea
ittenatherosclerotic diseases; in a Danish study, the association
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diseases, but this may have been due to the small numbers
involved.5
Cigarette smoking is a strong risk factor for AAA. The
risk is greater than, and independent of, the effect of
smoking on coronary heart disease.13,25 Smoking is a com-
mon cause of COPD and therefore may be a confounding
factor for the association between impaired lung function
and aneurysm. We found, however, that the relationship
between lung function (FEV1, PEFR, and FEV1/FVC)
and COPD with risk of aneurysm was independent of
lifetime cigarette smoking. An effect independent of a
history of smoking regularly was also found in the ADAM
study.3 The association of impaired pulmonary function
with aneurysm rupture has also been shown to be indepen-
dent of smoking.7,8 This independence does not, of course,
rule out some effect of smoking on both lung function and
aneurysm contributing to the association, perhaps medi-
ated by a common pathway such as inflammation.
Inflammation and activation of hemostasis (resulting in
a laminated luminal thrombosis) are important characteris-
tics of AAAs. An inflammatory infiltrate, including lympho-
cytes and macrophages, is present in the aneurysm adven-
titia and media and is associated with increased breakdown
of the extracellular matrix.16 Aneurysms have also been
shown to contain/secrete excess inflammatory cytokines,
including IL-6,14 which may enhance proteolysis in the
aneurysm wall.26 These cytokines increase the expression of
matrix metalloproteinase (MMP-9) in macrophages, which
are the primary source of this elastolytic proteinase16 and
are becoming recognized as having an important role in the
pathobiology of aneurysms.27 Circulating levels of cyto-
kines, including IL-1, IL-6, and tumor necrosis factor-	,
have also been found to be higher in patients with aneu-
rysms than in those with coronary heart disease or healthy
controls.15 Inflammatory cytokines are associated with
increased production of acute phase proteins such as
C-reactive protein and fibrinogen that are elevated in the
plasma of aneurysm patients.28,29 The extent to which
systemic activation of inflammation and hemostasis is a
cause or consequence (or both) of aneurysm formation is
unclear, however.
The role of systemic activation of inflammation and
hemostasis in explaining the increased risk of coronary
heart disease in those with COPD was investigated in the
Third National Health and Nutrition Examination Survey
(NHANES) in the United States.30 A reduced FEV1 was
associated with higher plasma fibrinogen and C-reactive
protein levels, confirming that activated inflammation and
hemostasis in COPD had both a low-grade systemic and
local effect. COPD and C-reactive protein were found to
have an additive effect in predicting risk of cardiac injury.
Higher levels of inflammatory proteins associated with
impaired lung function have been shown to occur indepen-
dently of smoking, and it has been suggested that genetic
polymorphisms predisposing to exaggerated inflammatory
responses may also be relevant.31 Nevertheless, the in-
creased risk of atherosclerotic cardiovascular disease inthose with COPD may be only partly related to inflamma-
tion. Other factors, such as high blood pressure and diabe-
tes mellitus, which also occur more commonly in those
with COPD, may be important.32,33
The inflammatory and hemostatic factor that had the
largest effect in reducing the association between impaired
lung function and aortic aneurysm was D-dimer, an indica-
tor of fibrin formation and degradation. We have shown in
earlier analyses of the Edinburgh Artery Study population
that D-dimer levels were higher in aneurysm cases than
controls,29 and this has been confirmed in subsequent
studies in Japan.34,35 Plasmin antiplasmin complexes, an
indicator of fibrinolytic activation, also had a considerable
confounding effect on the associations between lung func-
tion and aneurysms. Plasmin is a common activator of
proteolytic systems in aneurysmal degradation of the aortic
wall, and plasmin antiplasmin complexes have been shown
to be predictive of the rate of aneurysm growth.36 To our
knowledge, plasmin antiplasmin complex levels have not
been reported in relation to COPD, but given that most
inflammatory processes disturb the balance in coagulation
and fibrinolysis, it would not be surprising if plasmin anti-
plasmin complex levels were elevated, as has been shown in
patients with bronchial asthma.37
CONCLUSION
The association of reduced respiratory function in an-
eurysm cases in this study was not explained by either
cigarette smoking or cardiovascular disease but became
nonsignificant on adjusting for markers of inflammation
and hemostasis. We hypothesize that response to injury
(activation of inflammation and hemostasis) may be an
explanation of the association. We suggest further studies
(eg, of genotypes influencing inflammatory responses) to
test this hypothesis. The influence of inflammatory and
hemostatic factors on the association could, however, sim-
ply reflect an epiphenomenon in which these factors are a
marker for unknown biologic effects leading to formation
of aneurysm and lung disease.
We are grateful to Margaret Russell and Eileen Ker-
racher for collection of data on patients and Dr Paul Allan
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